PRESS RELEASE
15 October 2009

BioInvent Interim Report
1 January – 30 September 2009

- **In the Phase II study of the product candidate TB-402 for the prevention of thrombosis, the treatment of patients in the third and final 100 patient cohort was started in September.**
- **In August the U.S. Food & Drug Administration (FDA) approved the Company's application to initiate Phase I studies of the product candidate BI-505 for the treatment of Multiple Myeloma.**
- **All patients have been treated in the Phase I study with repeated doses of TB-403 for patients with advanced cancer.**
- **Technology transfer under the terms of the alliance with Roche on product candidate TB-403 triggered during the first quarter a success fee of EUR 5 million to BioInvent and ThromboGenics.**
- **The phase I trial of BI-204 was completed in the second quarter. The product candidate for the prevention of secondary events in patients with cardiovascular disease was well tolerated. The drug is being co-developed with Genentech, a wholly-owned member of the Roche Group.**
- **During the third quarter an agreement was reached with Mitsubishi Tanabe Pharma Corp. for research and development of antibody drugs.**
- **Net revenues for January - September 2009: SEK 60.6 million (229.0 including initial milestone payment of 187.6 relating to TB-403).**
- **Current investments together with cash and bank as of 30 September 2009: SEK 113.8 million (252.7).**
- **Cash flow from current operations and investment activities for January – September 2009: SEK -98.6 million (35.9).**
- **Loss after tax for January - September 2009 amounted to SEK -130.8 million (61.6) and the profit after tax per share was SEK -2.35 (1.11).**

BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects mainly within the areas of thrombosis, cancer and atherosclerosis.

Comments by the CEO

We now have the results for the first nine months of the year and I would like to describe how I expect BioInvent to develop over the next few months. The first Phase II programme, around TB-402, that the Company has been involved in continues to make good progress. Recruitment of patients in the third and final cohort is proceeding at the same pace as the two previous cohorts and we are expecting all patients to be included in the study by the end of the year. We are expecting to be able to report the results of the study at the end of the first half of 2010. The primary and secondary goals of the study are to establish the safety profile and to document an anti-thrombotic effect. Our hope is that the results will provide the basis for the concluding studies leading up to marketing approval. According to

our strategic plan, the studies will be conducted with a partner with a commercial franchise to ensure an optimal launch of this unique product.

We are in the process of starting our first clinical study on the important US market. In August the US Food & Drug Administration (FDA) approved our application to start Phase I studies with our product candidate BI-505 for the treatment of Multiple Myeloma. We are expecting to be able to include the first patient in the near future. Multiple Myeloma is a type of cancer for which there is a significant need for new treatment options. We have succeeded in engaging very well-respected clinicians to be involved in the programme. This, combined with the orphan drug status, means the conditions are optimal for the clinical study that is expected to take up to one and a half years to complete.

Within the collaboration programme with Roche on TB-403 for the treatment of cancer, all patients in the Phase I programme have now been treated and the results will be presented at a conference in Boston in November. The next milestone is the start of the Phase II programme that will be handled by Roche.

In the second quarter the Phase I programme was concluded with BI-204. The product candidate for the prevention of secondary events in patients with cardiovascular disease, is being developed in cooperation with Genentech, a wholly-owned member of the Roche Group. BioInvent and its partner Genentech are evaluating next steps in the clinical development path for BI-204.

All in all we are looking at a product portfolio in the immediate future where most of the projects are proceeding according to plan or ahead of the original schedule. Although we have a strong focus on developing our own product portfolio, we are still making commercial progress with customers who require access to our broad technology platform. In the third quarter we were able to add Mitsubishi Pharma to the group of partners who are basing the development of their own antibody drugs on BioInvent's validated antibody technology. This is also proof of the fact that we are attracting strong partners in the growing Japanese market. Revenues from these alliances make an important contribution enabling us to maintain our financial flexibility.

Finally, it is also gratifying to note that external observers commend our company - most recently by BioInvent nominated for the 5th Annual Scrip Awards in categories of Licensing Deal of the Year and Management Team of the Year. This means of course that expectations increase - expectations which we will do our utmost to meet!

Development projects

BioInvent is currently running four projects in the development phase. In the development phase the safety profile of the product candidate is tested in animal models, before testing safety and efficacy in clinical trials.

Thrombosis (TB-402)

TB-402 is a human antibody binding to Factor VIII. The antibody has shown a beneficial partial inhibition of Factor VIII, even when applied in excess dosage. This reduces the risk of undesirable bleedings. The objective is to initially develop a drug that prevents Deep Vein Thrombosis (DVT) following orthopaedic surgery. DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the US alone, more than 600,000 individuals are affected by DVT or pulmonary embolism (PE) each year. It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist. Patients undergoing hip replacement or knee surgery are particularly at risk of developing DVT and all patients are therefore treated with anticoagulants prophylactically in order to reduce the risks of blood clots. The project is carried out within the alliance with ThromboGenics.

Results from the Phase I trial show that TB-402 is both safe and well-tolerated. No serious adverse events related to TB-402 were reported. The pharmacokinetic analysis undertaken as part of the Phase I trial confirm a prolonged half-life of approximately three weeks, which will allow for single dose treatment in orthopaedic surgery patients and/or a once-a-month administration for long-term stroke prevention in atrial fibrillation (AF), as opposed to daily treatment with current anticoagulants. The pharmacodynamic analysis confirms that TB-402 achieves only partial inhibition of Factor VIII activity without the undesired effect of total inactivation. A stable long-acting anticoagulant effect based on partial Factor VIII inhibition could also be shown.

Additional studies have shown that the effect of TB-402 can be reversed by giving the target protein (Factor VIII) that blocks TB-402 and also that TB-402 is safe and well tolerated in patients that are

given standard treatment (enoxaparin and warfarin) for deep vein thrombosis. The results show that TB-402 has prospects to be developed into a safe and well-controlled treatment for several medical conditions in which thrombosis prevention is of great importance.

A Phase ll trial enrolling in total 300 patients was initiated in February 2009 for the prevention of DVT in patients who have received an artificial knee joint. Treatment of the 100 patients included in the second cohort was completed in August. Recruitment of 100 patients for the third and final cohort began in September. Recruitment for this dose cohort is also very good and the company expects that all patients will be included in the study by year-end. The results are expected to be reported at the end of the first half of 2010.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study assesses three different doses of TB-402 given as a single intravenous bolus injection post knee replacement surgery. The objective of the study is to assess the safety and efficacy of the three escalating doses of TB-402.

Atherosclerosis (BI-204)

The product candidate BI-204 targets oxidized forms of the LDL cholesterol (oxLDL). Links have been shown between oxidized forms of certain lipoproteins and the inflammatory processes that lead to plaque formation in the vessel walls. BI-204 has in preclinical studies reduced inflammatory processes and reduced plaque formation significantly. The results also show a considerable reduction in the size of existing plaques in animals treated with BI-204. Results supports that the mechanism behind BI-204 is a modulation of the inflammatory process resulting in a reduction of pro-inflammatory cells in treated plaques, which in turn leads to a reduction in new plaque formation and the regression of existing plaques. It is being developed as a drug for the prevention of secondary events in patients with cardiovascular disease. In a population-based, prospective, observational study of the risk of development of coronary artery disease (JAMA. 2008; 299 (19) 2287-2293) higher concentration of oxidized LDL was associated with increased incidence of metabolic syndrome overall, as well as its components of insulin resistance and hyperglycemia. These observations support the picture that oxidized LDL can be an important target structure for developing new medications to treat patients with type 2 diabetes and metabolic syndrome. BI-204 is developed in collaboration with Genentech, a wholly-owned member of the Roche Group.

The phase I programme was completed in the second quarter. The study was a double-blind, within-group randomised dose-escalation trial testing both single and multiple doses of BI-204 administered either intravenously or subcutaneously. In total, 80 healthy male or female subjects with elevated levels of LDL cholesterol were included in the trial. BI-204 was well tolerated and pharmacokinetic results showed the halflife was in the expected range for fully human antibodies. BioInvent and its partner Genentech are evaluating next steps in the clinical development path for BI-204.

Cancer (TB-403)

The product candidate TB-403, is a monoclonal antibody directed against placental growth factor, PlGF. TB-403 binds PlGF with high affinity and specificity and has been shown to inhibit tumour growth in animal models. TB-403 blocks tumour angiogenesis, the development of new blood vessels, which is required for tumour nutrient and oxygen supply supporting tumour growth. Angiogenesis is also required for disease progression and metastasis, the dissemination of the tumour to distal sites of the body.

The PlGF growth factor is secreted by tumours and is specifically over expressed in cancer and chronic inflammatory conditions. It affects the formation of new vessels in tissue that is under stress. PlGF is not required for survival of normal resting vasculature and blocking PlGF is expected to be relatively safe, because mice lacking PlGF are healthy and reproduce normally. Preclinical research has also shown that inhibition of PlGF does not induce resistance mechanisms because it does not induce “angiogenic rescue” mechanisms, whereby tumour expression of proangiogenic growth factors is upregulated that may enable escape from therapy. This angiogenic rescue phenomenon has been demonstrated with some angiogenesis inhibitors.

Up to June 2008 the project was carried out within the alliance with ThromboGenics. In June 2008 BioInvent and partner ThromboGenics entered into a strategic license agreement with Roche for development and commercialisation of TB-403. Roche received a worldwide, exclusive license to develop and commercialise TB-403. BioInvent and ThromboGenics retained co-promotion rights for the product in the Nordic, Baltic and Benelux regions.

The first Phase I study in 16 healthy male subjects was successfully completed in June 2008 and showed that TB-403 is safe and well tolerated, with pharmacokinetic properties enabling it to be developed as a novel anti-cancer agent. The follow-up study is a study of tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer. All patients have been treated in the study. The results will be reported at the AACR-NCI-EORTC's Molecular Targets and Cancer Therapeutics Conference in Boston the 16th of November 2009.

In January 2009 transfer and implementation of technology and process development to Roche in relation to the ongoing clinical development of TB-403 was successfully finalized. This triggered a success fee of EUR 5 million to BioInvent and ThromboGenics.

Cancer (BI-505)

The drug candidate BI-505 is a human antibody that targets the adhesion protein ICAM-1 (also called CD54). In tumour cells the expression of ICAM-1 is elevated and it is therefore a candidate for being a suitable target protein for a therapeutic antibody. In addition to inducing apoptosis the antibody also provides important immuno-effector functions that help to kill tumour cells. BI-505 has in different animal models proved to be very effective at killing tumours and more effective than existing drugs.

BioInvent's intention is, in an initial stage, to treat patients with multiple myeloma. Other forms of hematologic cancer may also become relevant as indications. The possibility of treating ICAM-1 expressing solid tumours will also be examined further in additional preclinical trials. The number of newly diagnosed patients with multiple myeloma is more than 40,000 per year and the number of newly diagnosed patients with blood cancer is more than 200,000 per year.

BI-505 has been granted orphan drug designation in the United States and Europe for the indication of multiple myeloma. This status gives BI-505 possibility for market exclusivity for treatment of multiple myeloma with an antibody against ICAM-1 in these markets for 10 years after marketing approval is obtained.

In August the U.S. Food & Drug Administration (FDA) approved the Company's application to initiate Phase I studies for the treatment of Multiple Myeloma. The first patient is expected to be included in the study in the near future.

Research projects

BioInvent is running a number of projects in the research phase i.e. the stage prior to selection of a Candidate Drug. The company's research portfolio currently includes projects mainly within the areas of cancer and inflammation. The research in the cancer field is aimed at additional product candidates that will impede undesirable vessel growth and thus the blood supply to tumours, as well as at apoptotic antibodies that kill tumour cells. BI-505 is one result of the apoptosis programme.

The company is also conducting research and development on antibody-based drugs on behalf of external partners. Such partners are Mitsubishi Tanabe Pharma and Bayer HealthCare, these agreements allows for up to 19 antibody products to be developed. As well as undisclosed license fees and research funding, BioInvent will receive milestone payments and royalties on sales of any products commercialized.

Revenues and result

Net revenues for the January – September period amounted to SEK 60.6 million (229.0). Reported net revenues include BioInvent's share, SEK 21.7 million, of the first milestone payment for TB-403. The milestone payment is for the successful technology transfer within the collaboration with Roche. BioInvent's share of the initial installment from Roche for TB-403, SEK 187.6 million is included in its entirety in reported net revenues for the second quarter 2008. Net revenues for the July – September period amounted to SEK 13.5 million (17.2).

The Company's total costs for the January – September period amounted to SEK 193.7 million (173.7). Operating costs are divided between external costs of SEK 122.1 million (108.8), personnel costs of SEK 63.2 million (56.5) and depreciation of SEK 8.4 million (8.4). Costs for toxicology studies and clinical studies, SEK 69 million, comprise the largest share of external costs. External costs have been reduced with research funding of SEK 12 million from development partners to cover their share of BioInvent's internal development costs.

Research and development costs for January – September amounted to SEK 168.8 million (150.6). Depreciation according to plan reduced the operating result for the period by SEK 8.4 million (8.4), of which depreciation of intangible fixed assets amounts to SEK 4.1 million (4.5).

The loss after tax for January – September amounted to SEK -130.8 million (61.6). The loss after tax for July - September amounted to SEK -42.6 million (-32.1). The net financial items, January – September, amounted to SEK 2.6 million (6.2). Earnings per share after tax, January – September, amounted to SEK -2.35 (1.11).

Financial position and cash flow

As of 30 September 2009, the Group's current investments together with cash and bank amounted to SEK 113.8 million (252.7). The cash flow from current operations and investment activities for January – September amounted to SEK -98.6 million (35.9). Last year a higher operating profit had a positive effect on cash flow. The improvement in cash flow is due to more capital tied up in short-term receivables (mainly accounts receivable) corresponding period previous year.

The shareholders' equity amounted to SEK 101.2 million (276.1) at the end of the period. The Company's share capital was SEK 27.8 million. The equity/assets ratio at the end of the period was 63.8 (77.8) per cent. Shareholders' equity per share amounted to SEK 1.82 SEK (4.96). The Group had no interest-bearing liabilities.

Investments

Investments in tangible fixed assets amounted to SEK 1.1 million (5.9). No investments were made in intangible assets during the period (6.0).

Organisation

As of 30 September 2009, BioInvent had 105 (100) employees. 89 (85) of these work in research and development.

Employee incentive program

The annual general meeting on 14 April 2008 resolved to adopt an incentive program comprising a maximum of 1,450,000 employee options (Sw. personaloptioner) and to issue 1,920,090 warrants for the subsidiary BioInvent Finans AB, free of charge, to secure the company's commitment under the incentive program and to cover the company's associated social security contributions. BioInvent Finans AB has subscribed all the warrants. Each employee option entitles the holder to subscribe to a new share at a subscription price of SEK 26.84. A basic allocation of 513,750 employee options took place during 2008 and 2009. Extra allotment of 69,750 employee options took place in February 2009.

The annual general meeting on 21 April 2009 resolved to adopt an amendment to the existing employee options program 2008/2012, resolved by the AGM 2008. The amendment program comprise a maximum of 240,250 employee options, directed to the employees of the Company, entitling the holder to subscribe for new shares. Each employee option entitles the holder to subscribe to a new share at a subscription price of SEK 26.84. A basic allocation of 22,500 employee options took place in June 2009.

Risk factors

The Company's operations are associated with risks related to factors such as drug development, competition, collaboration with partners, technology development, patents, capital requirements, currency and interest rates. The aforementioned risks summarize the factors of significance for BioInvent and thus an investment in the BioInvent share.

Accounting principles

For the group's part this interim report is prepared according to IAS 34, Interim Financial Reporting, and the Annual Accounts Act and for the parent company's part according to the Annual Accounts Act and the Swedish Financial Reporting Board's Recommendation RFR 2.2, Accounting for legal entities. The accounting principles applied are consistent with those used when preparing the most recent Annual Report with the following exceptions due to new or revised standards, interpretations and improvements adopted by the EU and which came into force on 1 January 2009: IFRS 8 Operating segments, revised IAS 1 Presentation of financial statements, IAS 23 Borrowing costs, IAS 32 Financial instruments, amendment to IAS 27 changing the rules for recognition of dividend revenue from subsidiaries, associates, and jointly controlled entities, and IFRIC 13 Customer Loyalty Programmes. The only change that affects the Group and the parent company is revised IAS 1 Presentation of financial statements. This standard divides changes in shareholders' equity resulting from transactions with owners and other changes. Reporting of changes in equity will only include details relating to owner-related transactions. Non-owner changes in equity are presented on a separate line in changes in equity. In addition, the standard concept "Statement of comprehensive

income" is being introduced, which shows all recognised income and expense items either in a single statement, or in two consecutive statements. The Group has chosen to present the Statement of comprehensive income in a single statement.

Annual General Meeting and upcoming financial reports

The Annual General Meeting will be held on Tuesday 20 April 2010 at 4 p.m., at Ideon, Lund. Details about the composition of the Nominating Committee will be posted on the web site.

BioInvent will present the following financial reports:

Financial statement for 2009	17 February 2010
Interim reports	15 April, 14 July, 14 October 2010

Contact

Any questions regarding this report will be answered by:

BioInvent International AB (publ.)
Svein Mathisen, President & CEO, tel.+46 (0)46 286 85 67, mobile +46 (0)708 97 82 13
Cristina Glad, Executive Vice President, tel. +46 (0)46 286 85 51, mobile +46 (0)708 16 85 70.

College Hill
Holly Griffiths, Sue Charles and John McIntyre, tel. +44 (0)20 7457 2020, bioinvent@collegehill.com

The report is also available at www.bioinvent.com

Consolidated statement of comprehensive income in brief for the Group (SEK thousands)

	3 MONTHS 2009 July-Sep.	3 MONTHS 2008 July-Sep.	9 MONTHS 2009 Jan.-Sep.	9 MONTHS 2008 Jan.-Sep.	12 MONTHS 2008 Jan.-Dec.
Net revenues	13,506	17,171	60,629	229,003	252,138
Operating costs					
Research and development costs	-48,210	-44,679	-168,800	-150,637	-215,434
Sales and administrative costs	-7,783	-7,438	-24,862	-23,023	-30,882
Other operating revenues and costs	-321	-34	-431	59	749
	-56,314	-52,151	-194,093	-173,601	-245,567
Operating profit/loss	**-42,808**	**-34,980**	**-133,464**	**55,402**	**6,571**
Profit/loss from financial investments	208	2,842	2,637	6,241	9,680
Profit/loss after financial items	**-42,600**	**-32,138**	**-130,827**	**61,643**	**16,251**
Tax	-	-	-	-	-
Profit/loss	**-42,600**	**-32,138**	**-130,827**	**61,643**	**16,251**
Other comprehensive income					
Changes in reserve, actual value	-37	-32	-186	-13	313
Comprehensive income	**-42,637**	**-32,170**	**-131,013**	**61,630**	**16,564**
Profit/loss pertaining to the parent company's shareholders	-42,637	-32,170	-131,013	61,630	16,564
Earnings per share, SEK					
Before dilution	-0.77	-0.58	-2.35	1.11	0.29
After dilution	-0.77	-0.58	-2.35	1.11	0.29

Consolidated statement of financial position in brief for the Group (SEK thousands)

	2009 30 Sep.	2008 30 Sep.	2008 31 Dec.
Assets			
Fixed assets			
Intangible fixed assets	8,296	13,989	12,384
Tangible fixed assets	13,217	16,217	16,427
Current assets			
Inventories etc.	2,690	3,596	2,304
Current receivables	20,458	68,254	51,852
Current investments	76,942	239,239	196,066
Cash and bank	36,882	13,482	16,394
Total assets	**158,485**	**354,777**	**295,427**
Shareholders' equity and liabilities			
Shareholders' equity	101,179	276,078	231,298
Current liabilities	57,306	78,699	64,129
Total shareholders' equity and liabilities	**158,485**	**354,777**	**295,427**

Statement of changes in equity for the Group (SEK thousands)

	2009 July-Sep.	2008 July-Sep.	2009 Jan.-Sep.	2008 Jan.-Sep.	2008 Jan.-Dec.
Opening balance	**143,503**	**307,976**	**231,298**	**214,118**	**214,118**
Effect of employee incentive program	313	272	894	330	616
Comprehensive income	-42,637	-32,170	-131,013	61,630	16,564
Closing balance	**101,179**	**276,078**	**101,179**	**276,078**	**231,298**
Shareholders' equity pertaining to the parent company's shareholders	101,179	276,078	101,179	276,078	231,298

The share capital as of 30 September 2009 consists of 55,660,889 shares and the share's ratio value is 0.5.

Consolidated statement of cash flows in brief for the Group (SEK thousands)

	2009 July-Sep.	2008 July-Sep.	2009 Jan.-Sep.	2008 Jan.-Sep.	2008 Jan.-Dec.
Current operations					
Operating profit/loss	-42,808	-34,980	-133,464	55,402	6,571
Depreciation	2,726	3,091	8,375	8,429	11,543
Interest received and paid	815	1,584	4,453	4,772	9,361
Cash flow from current operations before changes in working capital	**-39,267**	**-30,305**	**-120,636**	**68,603**	**27,475**
Changes in working capital	3,019	169,505	23,077	-20,813	-18,227
Cash flow from current operations	**-36,248**	**139,200**	**-97,559**	**47,790**	**9,248**
Investment activities					
Acquisition of intangible fixed assets	-	-6,001	-	-6,001	-6,001
Acquisition of tangible fixed assets	-471	-2,176	-1,077	-5,919	-7,638
Cash flow from investment activities	**-471**	**-8,177**	**-1,077**	**-11,920**	**-13,639**
Cash flow from current operations and investment activities	**-36,719**	**131,023**	**-98,636**	**35,870**	**-4,391**
Financing activities	**-**	-	-	-	**-**
Changes in current investments**	**79,907**	**-131,405**	**142,182**	**-84,874**	**-6,815**
Change in liquid funds	**43,188**	**-382**	**43,546**	**-49,004**	**-11,206**
Opening liquid funds	51,638	13,864	51,280	62,486	62,486
Liquid funds at end of period	**94,826**	**13,482**	**94,826**	**13,482**	**51,280**
Liquid funds, specification:					
Current investments that constitute liquid funds*	57,944	-	57,944	-	34,886
Cash and bank	36,882	13,482	36,882	13,482	16,394
	94,826	**13,482**	**94,826**	**13,482**	**51,280**
Current investments**	18,998	239,239	18,998	239,239	161,180
	113,824	**252,721**	**113,824**	**252,721**	**212,460**

*Duration less than 3 months
**Duration more than 3 months

Key financial ratios for the Group

	2009 30 Sep.	2008 30 Sep.	2008 31 Dec.
Shareholders' equity per share at end of period, SEK			
Before dilution	1.82	4.96	4.15
After dilution	1.82	4.96	4.15
Number of shares at end of period			
Before dilution (thousands)	55,661	55,661	55,661
After dilution (thousands)	55,661	55,661	55,661
Equity/assets ratio, %	63.8	77.8	78.3
Number of employees at end of period	105	100	103

Consolidated income statement in brief for the Parent Company (SEK thousands)

	9 MONTHS 2009 Jan.-Sep.	9 MONTHS 2008 Jan.-Sep.	12 MONTHS 2008 Jan.-Dec.
Net revenues	60,629	229,003	252,138
Operating costs			
Research and development costs	-168,075	-150,370	-214,933
Sales and administrative costs	-24,692	-22,960	-30,767
Other operating revenues and costs	-431	59	749
	-193,198	-173,271	-244,951
Operating profit/loss	**-132,569**	**55,732**	**7,187**
Profit/loss from financial investments	2,637	6,241	9,680
Profit/loss after financial items	**-129,932**	**61,973**	**16,867**
Tax	**-**	**-**	**-**
Profit/loss	**-129,932**	**61,973**	**16,867**

Consolidated balance sheet in brief for the Parent Company (SEK thousands)

	2009 30 Sep.	2008 30 Sep.	2008 31 Dec.
Assets			
Fixed assets			
Intangible fixed assets	8,296	13,989	12,384
Tangible fixed assets	13,217	16,217	16,427
Financial fixed assets	100	100	100
Current assets			
Inventories etc.	2,690	3,596	2,304
Current receivables	20,458	68,227	51,852
Current investments	76,932	239,369	195,870
Cash and bank	36,882	13,482	16,394
Total assets	**158,575**	**354,980**	**295,331**
Shareholders' equity and liabilities			
Shareholders' equity	101,183	276,221	231,115
Current liabilities	57,392	78,759	64,216
Total shareholders' equity and liabilities	**158,575**	**354,980**	**295,331**

Lund, 15 October 2009

Svein Mathisen, President and CEO

Review report

Introduction
We have reviewed the summarised interim financial information for BioInvent International AB (publ) for the period 1 January 2009 – 30 September 2009. The board of directors and the CEO are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of review
We conducted our review in accordance with the Standard on Review Engagements SÖG 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing in Sweden RS and other generally accepted auditing practices. The procedures performed in a review do not enable us to obtain a level of assurance that would make us aware of all significant matters that might be identified in an audit. Therefore, the conclusion expressed based on a review does not give the same level of assurance as a conclusion expressed based on an audit.

Conclusion
Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, for the group's part according to IAS 34 and the Annual Accounts Act and for the parent company's part according to the Annual Accounts Act.

Lund, 15 October 2009
ERNST & YOUNG AB

Johan Thuresson
Authorised Public Accountant

BioInvent International AB (publ.)
Co. reg. no. 556537-7263
Address: Sölvegatan 41, 223 70 Lund
Tel.: +46 (0)46 286 85 50
info@bioinvent.com

Legal disclaimer
This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual out-come may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 15 October, 2009.